MTPH.L Share Price (MTPH)

Not good for holders

Just checked what my shares are worth

FC.k all really

Shouldnt be allowed to do what they did......

Ten grand down the toilet. Held these for six years. Was stupid back then obviously. Loss aversion stopped me taking a hit earlier and now that ten grand is worth less than a hundred quid. The money was hard earned.

This BoD has blood on their hands.

Biodesix has a Market Cap of 134.897M and my broker has it on platform .
No idea what BIODEXA Market Cap is ? My broker will not add on platform .

BIODEXA Can not find any info on this one .

This company has very similar name Biodesix ( hopefuly completely different company )
However, the company will have to raise $15 million in funding to extend the loan repayment date, with the $11.7 million raised via the private placement counting towards the final amount.
Interestingly, these announcements were made yesterday, yet Biodex shares rally today, indicating a delayed response to the news.
Biodesix’s shares have fallen 69.94% in 2022 despite the company making significant progress towards its goal of transforming the lung diagnostic testing industry.
The company recently published new data in a peer-reviewed journal validating the use of liquid biopsies and NGS techniques to provide clinical information for patients with cancer.
Scott Hutton, Biodesix’s CEO, said: “This transaction marks another important milestone in the Company's effort to build an enduring business that will fundamentally change the lung diagnostic testing industry. This transaction strengthens our ability to achieve our vision, and we could not be more excited about what the future holds for Biodesix,”
“We believe the continued confidence and commitment demonstrated by some of our largest shareholders is a testament to our business model, the strength of our team and the huge market opportunity in front of us.”
Biodesix’s executives have also been acquiring shares in the company, as evidenced by Matthew Strobeck’s, one of the company’s directors’ acquisition of 558,659 BDSX shares at $1.79 per share on April 7, 2022. Of course, it's always good to see company insiders buying shares.
Investors did not react significantly to the latest releases from Biodesix despite the significant progress made by the company. However, today’s rally might signify that the worst is over for the biotech firm. Hopefully, the rally translates into a sustained uptrend.